Enanta Pharmaceuticals (ENTA) Downgrade
RBC Capital cut shares of Enanta Pharmaceuticals (ENTA) from “Outperform” rating to “Sector Perform” rating in a research note issued to clients and investors on Tuesday morning.
The rating downgrade was most probably noticed by stock traders, as ENTA is now trading 0.00% lower at $0.00 as of 10:06 PM New York time. Enanta Pharmaceuticals’s stock is 0% over the past 200 days. It has underperformed the S&P500, which has increased 6.00% over the same time.
Krensavage Asset Management Llc had the most significant stake with ownership of 999,741 shares as of Q2 2015 for 9.61% of the US long stock exposure. Great Point Partners Llc is another very bullish fund who is having 790,000 shares of Enanta Pharmaceuticals or 5.36% of their US long stock exposure. Further, Mcclain Value Management Llc have 3.91% of their US long stock exposure invested in the company for 183,086 shares. The New York-based fund Armistice Capital Llc revealed it had purchased a stake worth about 1.81% of the fund’s stock portfolio in Enanta Pharmaceuticals. The New York-based fund Ghost Tree Capital Llc is also positive about the stock, possessing 212,000 shares or 1.08% of their US long stock exposure.
Enanta Pharmaceuticals (ENTA) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Enanta Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest Enanta Pharmaceuticals (ENTA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post EU: Enanta Pharmaceuticals (ENTA) Rating Decreased to “Sector Perform” at RBC Capital. Lost Its “Outperform” Rating appeared first on Octafinance.